Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma

Human Pathology

Volumn 41, Issue 2, 2010, Pages 255-261

  Zhang, Cunxian ^a,b   Wang, Yu Edmond ^a,b   Zhang, Peng ^a,b   Liu, Fang ^a,b   Sung, C James ^a,b   Steinhoff, Margaret M ^a,b   Quddus, M Ruhul ^a,b   Lawrence, W Dwayne ^a,b  

^a WOMEN AND INFANTS HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Ovarian serous borderline tumor

Indexed keywords

SELENIUM BINDING PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CARCINOGENESIS; CELL PROLIFERATION; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MICROPAPILLARY SEROUS BORDERLINE TUMOR; OVARIAN SEROUS BORDERLINE TUMOR; OVARY TUMOR; PROTEIN EXPRESSION; SEROUS CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYSTADENOCARCINOMA, SEROUS; CYSTADENOMA, SEROUS; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; SELENIUM-BINDING PROTEINS;

EID: 73749086834     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.07.019     Document Type: Article

References (17)

1. Seidman J.D., Soslow R.A., Vang R., et al. Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol 35 (2004) 918-933
2. Shih I.M., and Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164 (2004) 1511-1518
3. Shih I.M., and Kurman R.J. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Hum Cancer Res 11 (2005) 7273-7279
4. Huang K.C., Park D.C., Ng S.K., et al. Selenium binding protein 1 in ovarian cancer. Int J Cancer 118 (2006) 2433-2440
5. Clark L.C., Combs G.F., Turnbull B.W., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276 (1996) 1957-1963
6. Fleming J., Ghose A., and Harrison P.R. Molecular mechanisms of cancer prevention by selenium compounds. Nutr Cancer 40 (2001) 42-49
7. Rayman M.P. The importance of selenium to human health. Lancet 356 (2000) 233-241
8. Yang M., and Sytkowski A.J. Differential expression and androgen regulation of the human selenium-binding protein gene hSP56 in prostate cancer cells. Cancer Res 58 (1998) 3150-3153
9. Chen G., Wang H., Miller C.T., et al. Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol 202 (2004) 321-329
10. Kim H., Kang H.J., You K.T., et al. Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 6 (2006) 3466-3476
11. Stammer K., Edassery S.L., Barua A., et al. Selenium-binding protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer. Gynecol Oncol 109 (2008) 115-121
12. Silverberg S.G., Bell D.A., Kurman R.J., et al. Borderline ovarian tumors: key points and workshop summary. Hum Pathol 35 (2004) 920-927
13. Bansal M.P., Mukhopadhyay T., Scott J., Cook R.G., Mukhopadhyay R., and Medina D. DNA sequencing of a mouse liver protein that binds selenium: implications for selenium's mechanism of action in cancer prevention. Carcinogenesis 11 (1990) 2071-2073
14. Ho C.L., Kurman R.J., Dehari R., Wang T.L., and Shih I.M. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 64 (2004) 6915-6918
15. Combs G.F., and Gray W.P. Chemopreventive agents: selenium. Pharmacol Ther 79 (1998) 179-192
16. Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr 128 (1998) 1845-1854
17. Medina D. Mechanisms of selenium inhibition of tumorigenesis. Adv Exp Med Biol 206 (1986) 465-472